Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a hormone involved in regulating blood sugar levels and appetite.
By mimicking the effects of GLP-1, Semaglutide helps lower blood glucose levels and reduces slow gastric appetite, which leads to decreased food intake.
**Weight Loss Efficacy: **
Clinical trials have demonstrated that Semaglutide can lead to significant weight loss. Some studies have reported that individuals taking Semaglutide lost an average of 12-15% of their body weight over 68 weeks.
The drug has been approved by the FDA for weight management under the brand name Wegovy for adults with obesity or overweight individuals with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol.